Annovis Bio Inc (ANVS) Stock Price, Quote & News

Company Profile

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 2/3 to treat alzheimer's disease, as well as in phase 3 to treat parkinson's disease; and is in phase 2 clinical trial to treat lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phas...

Industry: Biotechnology

Sector: Healthcare

Phone: 484 875 3192

Website: www.annovisbio.com

Address:

101 Lindenwood Drive, Suite 225, Malvern, United States

5DollarNana Mar. 20 at 3:29 PM

$ANVS 3 in no time then $6 then $9 then $12!!!!!

1 · Reply

trichomy Mar. 20 at 9:51 AM

$INMB $INMB SYSTEMIC VALUATION ERROR 🚨 At a ~$37M cap, the lattice is completely mispricing the clinical actuality. Shorts are trapped in a highly illiquid float. 🧬 XPro: Phase 2b/3 registrational pathway locked. FDA alignment on the pTau217 biomarker is a massive de-risking event post AD/PD 2026. 🇬🇧 CORDStrom: UK MAA filing pending mid-summer. Institutions are anchoring to the Lucid $9 PT, but the historical actuality dictates the $11.00 Restoration. The mechanical squeeze is coiling. Let the algorithms chew through the resistance. #VictoryForTheBaby #Alzheimers #Biotech $SAVA $ANVS $XBI

1 · Reply

NolAsrtormZ Mar. 20 at 3:52 AM

$ALZN remember $SAVA and $ANVS phase 2 results went over $100 a share Data end of march Share float small

1 · Reply

zshortcut Mar. 19 at 8:04 PM

$ANVS interesting rejection.

0 · Reply

Kayhless Mar. 19 at 7:22 PM

$ANVS This is real OBJECTIVE data they will be getting people. MEASURABLE, solid data not I think my tremors and or spasms are less, it will be measurable with this data. It’s a good tool, like they use for diabetics when they wear the patch and get 24/7 reaction data and heart monitors to name a couple. The drug works, this will record that progress one way or the other. Going thru a third party will keep it honest. Maria obviously believes in this drug and she wants to prove it. Go Maria and ANVS team!

0 · Reply

zshortcut Mar. 19 at 6:26 PM

$ANVS ?

0 · Reply

RockDoctor Mar. 19 at 4:45 PM

$ANVS this announcement is bearish. the LAST thing this company needs given its reputation of spinning results is to introduce a data collection mechanism that is extraneous to meeting their stated endpoints for regulatory approval

3 · Reply

Kayhless Mar. 19 at 3:48 PM

$ANVS This is actually very good news. This will provide actual objective data related to tremors and non voluntary movements in real time. Measurable results! This is fantastic IMO. Less expensive I would think as well as way more data.

0 · Reply

ppl_first Mar. 19 at 3:38 PM

$ANVS The type of PR this morning was to keep the story alive while waiting for real data. Not bullish, bearish, or investable information. If anything, it raises a caution flag for interim hype instead of real clinical data or efficacy. It's a measurement tool upgrade. Doctors care about if it works, how well it works, and if it's safe, not if the clinical trial had AI wearables.

0 · Reply

junkjar291 Mar. 19 at 2:31 PM

$ANVS This will be on OTC by end of the year, trading in penny land.

0 · Reply

Annovis Partners with NeuroRPM to Deploy AI-Powered Digital Biomarker Technology in Parkinson's Disease Study

Mar 19, 2026, 7:30 AM EDT - 2 days ago

NeuroRPM to Deploy AI-Enabled Digital Biomarker Monitoring for Annovis Bio's Parkinson's Disease Clinical Trial

Mar 16, 2026, 7:30 AM EDT - 5 days ago

Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results

Mar 3, 2026, 8:00 AM EST - 18 days ago

Annovis Announces Two Presentations at the AD/PD™ 2026 International Conference

Feb 12, 2026, 8:00 AM EST - 5 weeks ago

Annovis Secures DSMB Approval to Advance Pivotal Phase 3 Trial of Buntanetap in Alzheimer's Disease

Dec 18, 2025, 4:35 PM EST - 3 months ago

Annovis Announces Open-Label Extension Study for Parkinson's Disease Patients

Dec 16, 2025, 8:00 AM EST - 3 months ago

Annovis to Host Corporate Update Webinar on January 28, 2026

Dec 3, 2025, 8:00 AM EST - 3 months ago

Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group

Nov 24, 2025, 8:00 AM EST - 4 months ago

Annovis Announces Two Presentations at the CTAD 2025 Conference

Nov 18, 2025, 8:00 AM EST - 4 months ago

Annovis Announces FDA Meeting to Discuss Parkinson's Disease Dementia Program; Reaffirms FDA Alignment on Pivotal Phase 3 Alzheimer's Disease Study

Nov 17, 2025, 1:07 PM EST - 4 months ago

Annovis Bio Stock Jumps As New Data Shows Buntanetap Halts Cognitive Decline In Parkinson's Patients

Nov 17, 2025, 8:00 AM EST - 4 months ago

Annovis Reports New Biomarker Data Linking Amyloid Co-Pathology to Accelerated Cognitive Decline in Parkinson's Patients

Nov 12, 2025, 8:00 AM EST - 4 months ago

Annovis Provides Corporate Updates and Reports Third Quarter 2025 Financial Results

Nov 6, 2025, 8:00 AM EST - 4 months ago

Annovis Achieves Significant Milestones and Sustains Strong Progress in Phase 3 Alzheimer's Program

Oct 27, 2025, 8:00 AM EDT - 5 months ago

Annovis Announces $3.4 Million Registered Direct Offering of Common Stock Priced At-the-Market under the NYSE Rules

Oct 15, 2025, 5:15 PM EDT - 5 months ago

Annovis Announces Closing of $6 Million Registered Direct Offering of Common Stock

Oct 10, 2025, 8:31 AM EDT - 5 months ago

Annovis Announces $6 Million Registered Direct Offering of Common Stock

Oct 9, 2025, 7:30 AM EDT - 5 months ago

Annovis Announces Novel Biomarker Data in Alzheimer's Patients Supporting Buntanetap's Potential as a Disease-Modifying Treatment

Sep 25, 2025, 7:30 AM EDT - 6 months ago

Annovis Appoints Mark Guerin as Chief Financial Officer

Sep 16, 2025, 7:30 AM EDT - 6 months ago

Annovis Reports Peer-Reviewed Publication Highlighting Pharmacokinetics of Novel Crystal Buntanetap

Sep 2, 2025, 8:00 AM EDT - 7 months ago

Annovis to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 12, 2025, 4:05 PM EDT - 7 months ago

Annovis Provides Corporate Updates and Reports Second Quarter 2025 Financial Results

Aug 7, 2025, 8:00 AM EDT - 8 months ago

Annovis Completes Full Patent Transfer to Crystal Buntanetap

Jun 26, 2025, 8:00 AM EDT - 9 months ago

Annovis to Attend the AAIC 2025 with Four Poster Presentations

Jun 19, 2025, 6:30 AM EDT - 9 months ago

Annovis Announces NYSE Acceptance of Plan to Regain Listing Compliance

Jun 5, 2025, 8:00 AM EDT - 10 months ago

Annovis to Host Webinar and Live Q&A on June 24, 2025

May 13, 2025, 4:30 PM EDT - 11 months ago

Annovis Provides Corporate Updates and Reports First Quarter 2025 Financial Results

Apr 29, 2025, 8:00 AM EDT - 11 months ago

Annovis Bio Appoints Hui Liu as Director of Biostatistics

Mar 27, 2025, 4:30 PM EDT - 1 year ago

Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE

Mar 25, 2025, 8:00 AM EDT - 1 year ago

Annovis to Attend AD/PD™ 2025 with Extensive Scientific Program

Mar 21, 2025, 5:05 PM EDT - 1 year ago

Annovis Provides Corporate Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results

Mar 11, 2025, 8:00 AM EDT - 1 year ago

Annovis Joins Experts at Drug Development Summit to Redefine Parkinson's Treatment

Feb 19, 2025, 8:30 AM EST - 1 year ago

Annovis to Host Patients' Live Forum on February 27, 2025

Feb 7, 2025, 8:00 AM EST - 1 year ago

Annovis to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Feb 5, 2025, 8:00 AM EST - 1 year ago

Annovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer's Disease

Feb 4, 2025, 4:31 PM EST - 1 year ago

Annovis Bio, Inc. Announces Closing of $21 Million Public Offering

Feb 3, 2025, 6:22 AM EST - 1 year ago

Annovis Bio, Inc. Announces Pricing of $21 Million Public Offering

Jan 31, 2025, 8:14 PM EST - 1 year ago

Annovis Bio, Inc. Announces Proposed Public Offering

Jan 14, 2025, 8:00 AM EST - 1 year ago

Annovis Granted U.S. Patent for Treatment and Prevention of Acute Brain or Nerve Injuries Securing Global Protection

Dec 5, 2024, 8:30 AM EST - 1 year ago

Annovis CEO Showcases Groundbreaking Advances in Neurodegenerative Disease Treatment on Today's Marketplace

Dec 4, 2024, 2:21 PM EST - 1 year ago

/C O R R E C T I O N -- Today's Marketplace/

Nov 25, 2024, 8:00 AM EST - 1 year ago

Annovis to Host Year-End Investor Webcast on December 11, 2024

Oct 31, 2024, 8:00 AM EDT - 1 year ago

IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Maria Maccecchini, CEO of Annovis Bio

Oct 15, 2024, 8:00 AM EDT - 1 year ago

FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer's Studies, Paving the Way to NDAs

Oct 3, 2024, 8:30 AM EDT - 1 year ago

Annovis Bio Inc. (NYSE: ANVS) Leading Way in Development of Safe, Effective Drugs for Neurodegenerative Diseases

Oct 2, 2024, 8:30 AM EDT - 1 year ago

Annovis Bio Inc. (NYSE: ANVS) Research Points to Potential Future Breakthroughs in AD Space Through Innovative Combinations

Sep 5, 2024, 8:00 AM EDT - 1 year ago

Annovis Bio (NYSE: ANVS) to Present at H.C. Wainwright 26th Annual Global Investment Conference

Aug 6, 2024, 8:00 AM EDT - 1 year ago

Annovis' Lead Compound Enhances Cognition Synergistically with GLP-1 Agonist

Jul 24, 2024, 8:00 AM EDT - 1 year ago

Annovis Bio Secures U.S. Patent for Treatment of Acute Traumatic Brain Injury with Buntanetap

Jul 2, 2024, 4:13 PM EDT - 1 year ago

Annovis stock more than doubled on Tuesday: what happened?

5DollarNana Mar. 20 at 3:29 PM

$ANVS 3 in no time then $6 then $9 then $12!!!!!

1 · Reply

trichomy Mar. 20 at 9:51 AM

1 · Reply

NolAsrtormZ Mar. 20 at 3:52 AM

$ALZN remember $SAVA and $ANVS phase 2 results went over $100 a share Data end of march Share float small

1 · Reply

zshortcut Mar. 19 at 8:04 PM

$ANVS interesting rejection.

0 · Reply

Kayhless Mar. 19 at 7:22 PM

0 · Reply

zshortcut Mar. 19 at 6:26 PM

$ANVS ?

0 · Reply

RockDoctor Mar. 19 at 4:45 PM

3 · Reply

Kayhless Mar. 19 at 3:48 PM

0 · Reply

ppl_first Mar. 19 at 3:38 PM

0 · Reply

junkjar291 Mar. 19 at 2:31 PM

$ANVS This will be on OTC by end of the year, trading in penny land.

0 · Reply

To_De_Moon Mar. 19 at 1:34 PM

$ANVS awesome news, time to speed uphttps://www.tipranks.com/news/the-fly/annovis-bio-enters-partnership-with-neurorpm-thefly-news?utm_source=webullapp.com&utm_medium=referral

0 · Reply

moneyonthebrain Mar. 19 at 12:24 PM

$ANVS I think the most noteworthy part of this morning's PR is that there are already 90 people enrolled in the new Parkinson's trial - those folks were obviously motivated to get back on buntanetap - another sign that the drug has a clear benefit for Parkinson's patients...

2 · Reply

moneyonthebrain Mar. 19 at 12:15 PM

$ANVS https://www.annovisbio.com/press-release/annovis-partners-with-neurorpm-to-deploy-ai-powered-digital-biomarker-technology-in-parkinsons-disease-study

0 · Reply

junkjar291 Mar. 18 at 3:27 PM

$ANVS POS back to where it was last week. Maria need to do her $20B dance to pump this by $0.05

2 · Reply

moneyonthebrain Mar. 17 at 10:39 PM

$ANVS just needs attention. Phase 3 is well underway with great phase 2 cognitive data to back it up. This is a pill to address some of the biggest unmet medical needs facing humanity. AVXL might bring some eyes here if it manages to get approved in Europe. Otherwise, more patients are on buntanetap each week and their positive stories might reach some well-resourced ears...

3 · Reply

To_De_Moon Mar. 17 at 8:13 PM

$ANVS

0 · Reply

Smuttlee Mar. 17 at 5:23 PM

$ANVS .

1 · Reply

junkjar291 Mar. 17 at 4:58 PM

$ANVS The reality is sinking in. The company has very little cash—$19.5M as of Dec 31, and the current amount may be around $12–13M and enrollment is very slow.

2 · Reply

wgreystone Mar. 17 at 1:37 PM

$ANVS it was 40% during the 1/28 webinar. Making quick progress.

1 · Reply

totti09 Mar. 17 at 1:37 PM

$ANVS

0 · Reply

focafoca99 Mar. 17 at 6:32 AM

$ANVS is still leaning on buntanetap data from that Phase 2/3 AD study and the biomarker angle feels like the real hook here.

0 · Reply

Fritzipooch Mar. 16 at 7:32 PM

$ANVS As a lay person in bio I found this very easy to read assessment of ANVS very informative and helps to provide me a level of confidence to just hang in there and be patient. https://www.merlintrader.com/annovis-bio-deep-dive-march-2026/

1 · Reply

Market Cap	70.04M
Revenue (ttm)	0.00
Net Income (ttm)	-24.59M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	746,100
Avg Vol	435,074
Day's Range	N/A - N/A
Shares Out	28.36M
Stochastic %K	43%
Beta	1.32
Analysts	Strong Sell
Price Target	$11.67